Older Male Adults In The Late 60

Older male adults in the late 60

[Author Name(s), First M. Last, Omit Titles and Degrees]

[Institutional Affiliation(s)]

Author Note

[Include any grant/funding information and a complete correspondence address.]

Synthesis Grid

Author

Purpose/Aim

Methodology

Sample

Findings

Themes

Similarities

Uniqueness

(De Ruysscher et al., 2006)

Identification of (T) time factors in a (C) combination of chemotherapy and radiotherapy in the population having small cell carcinoma (P) to increase years of life.

To check the effect of the duration of chest radiation from start to end of treatment in controlling indigenous tumors using meta-analysis procedure.

Elderly 60 years old people having small cell carcinoma.

There is an association found but very low, from the first day to the last day of treatment which means a positive association and it will increase the improved survival.

Combination

therapy

All of the studies done so far have suggested that the overall time of the radio-chemotherapy treatment is the supreme relevant predictor for consequences. Radiation therapy along with chemotherapy is useful in advanced stage carcinomas. Both have almost same side effects individually including hair loss, anemia and fatigue.

Several studies in murine tumor models proved that chemotherapy may induce accelerated repopulation Clinically, a few studies have shown a growth in cellular propagation after chemotherapy, at least in some patients.

(Shaw, et al, 2013)

The comparison (C) of Crizotinib (I) versus Chemotherapy in lung cancer patients (P) over time to enhance quality of life

open-label trial parallel to crizotinib with chemotherapy in patients having advanced or metastatic ALK-positive lung cancer.

Sample of 70 elderly persons with postoperative period.

Crizotinib is greater and influential to typical chemotherapy in patients treated.

Comparison study

The regular progression-free endurance was 7.7 months in the crizotinib group. Patients reported greater decreases in symptoms of lung cancer and superior development in quality of life with crizotinib than with chemotherapy.

Better results of Crizotinib treatment therapy as it is more advanced and have shown less toxicity in patients.

ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"a1t260sdcjl","properties":{"formattedCitation":"(Mehra, Moore, Crothers, Tetrault, & Fiellin, 2006)","plainCitation":"(Mehra, Moore, Crothers, Tetrault, & Fiellin, 2006)"},"citationItems":[{"id":128,"uris":["http://zotero.org/users/local/ONknjWue/items/NADQPGN4"],"uri":["http://zotero.org/users/local/ONknjWue/items/NADQPGN4"],"itemData":{"id":128,"type":"article-journal","title":"The association between marijuana smoking and lung cancer: a systematic review","container-title":"Archives of internal medicine","page":"1359-1367","volume":"166","issue":"13","author":[{"family":"Mehra","given":"Reena"},{"family":"Moore","given":"Brent A."},{"family":"Crothers","given":"Kristina"},{"family":"Tetrault","given":"Jeanette"},{"family":"Fiellin","given":"David A."}],"issued":{"date-parts":[["2006"]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} (Deng et al, 2013)

Complementary Treatments (I) along with integrated medication (C) for the treatment of patients with Lung Cancer (P) to improve patient’s health status over time (T)

Studies evaluating the treating therapies and their results were takes for the study.

A number of randomized control trials along with other cohort studies were analyzed to check results of systematic approach and complementary treatment of lung carcinoma. Population of older people with lung carcinoma.

Various complementary treatment with modalities can be cooperative in improving and enhancing the overall health of patients with lung carcinoma.

comparison therapy

Both therapies intended to improve quality of life in patients with carcinoma yet, medication and other chemotherapies and radiation therapy were observed with severe side effects.

Least side effects and improved quality of life was evaluated from the results of integrated therapies such as exercise, improved nutrition and

(Rossi et al., 2012)

To identify and (C) compare the efficacy of cisplatin or carboplatin based chemotherapy (I) for the (O) treatment of small cell lung cancer in elderly population (P)

A randomized control study was designed and data was collected from the centers providing first line treatment to population with small cell carcinoma in lungs.

Randomized control trials from centers providing treatment to population with small cell carcinoma in lungs.

It has been observed that there is no significant difference in treatment with of cisplatin or carboplatin based chemotherapy in patients with small cell lung cancer.

Correlation

Both are similar in treating the condition but toxicity varies. It has been observed in the study that cisplatin treatment was better than the carboplatin therapy.

Cisplatin based chemotherapy was diagnosed with better results and low toxicity

ADDIN ZOTERO_ITEM CSL_CITATION {"citationID":"a119c3d77vb","properties":{"formattedCitation":"(Schiller et al., 2002)","plainCitation":"(Schiller et al., 2002)"},"citationItems":[{"id":130,"uris":["http://zotero.org/users/local/ONknjWue/items/JHWABUPE"],"uri":["http://zotero.org/users/local/ONknjWue/items/JHWABUPE"],"itemData":{"id":130,"type":"article-journal","title":"Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer","container-title":"New England Journal of Medicine","page":"92-98","volume":"346","issue":"2","author":[{"family":"Schiller","given":"Joan H."},{"family":"Harrington","given":"David"},{"family":"Belani","given":"Chandra P."},{"family":"Langer","given":"Corey"},{"family":"Sandler","given":"Alan"},{"family":"Krook","given":"James"},{"family":"Zhu","given":"Junming"},{"family":"Johnson","given":"David H."}],"issued":{"date-parts":[["2002"]]}}}],"schema":"https://github.com/citation-style-language/schema/raw/master/csl-citation.json"} (Schiller et al., 2002)

A randomized control trial in elderly people (P) with non small cell lung carcinoma to (C)compare the three chemotherapies in comparison with cisplatin and paclitaxel(I) to see the improvement in patients over time. (T).

patients with advanced non–small-cell lung malignancy were randomly assigned to a reference regimen of cisplatin and paclitaxel or one of three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel.

Conduct with cisplatin and gemcitabine was related to a considerably time-consuming procedure to the growth of disease than was management with cisplatin and paclitaxel.

There was no significant advantage of four of the chemotherapy regimens in the management of progressive non–small-cell lung carcinoma.

Comparison

Chemotherapy for progressive non–small-cell lung carcinoma is often reflected as unproductive or extremely toxic.

In association with sympathetic care, chemotherapy consequences are with a small improvement in survival in patients with lung carcinoma.

Knowledge Gap with suggestions and recommendations

The objective of the literature review is to notify the physicians and research organizations that there should be an organized methodology for the patients in diagnostics and management of chemotherapy and radiation therapy. PICO analysis of different factors in the grid has strongly suggested that there is a need to improve the benefits of different therapies used. These is a need of significant researches to reduce the harms associated with various options of therapies to control lung cancer especially chemotherapy and radiation therapy. Publications and knowledge gap would be covered by providing cancer related studies and guidelines to develop a more obvious and transparent method to a PICO-based evaluation.

References

ADDIN ZOTERO_BIBL {"custom":[]} CSL_BIBLIOGRAPHY Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M. J., ... & Wu, Y. L. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New England Journal of Medicine, 368(25), 2385-2394.

Deng, G. E., Rausch, S. M., Jones, L. W., Gulati, A., Kumar, N. B., Greenlee, H., ... & Cassileth, B. R. (2013). Complementary therapies and integrative medicine in lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5), e420S-e436S.

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., … Johnson, D. H. (2002). Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. New England Journal of Medicine, 346(2), 92–98.

De Ruysscher, D., Pijls-Johannesma, M., Bentzen, S. M., Minken, A., Wanders, R., Lutgens, L., ... & Vansteenkiste, J. (2006). Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol, 24(7), 1057-1063.

Rossi, A., Di Maio, M., Chiodini, P., Rudd, R. M., Okamoto, H., Skarlos, D. V., ... & Shibata, T. (2012). Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. Journal of Clinical Oncology, 30(14), 1692-1698..